Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Oncology and Biosimilar Sub-Report offers credible, relevant insights related to oncology (IV vs. oral) and biosimilar files to support a company’s reimbursement forecasting needs.

WHY DO YOU NEED THIS SUB-REPORT?

The CRaFT Oncology and Biosimilar Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the oncology and biosimilar public market reimbursement process – from HTA submission to provincial listing.

WHAT DOES THE REPORT INCLUDE?

This CRaFT Oncology and Biosimilar Sub-Report includes 50+ page of insights on IV and oral oncology drugs related to:

  • CADTH review volume & timeline
  • pCPA volume for initiated, completed, closed, and not-negotiated files
  • pCPA under-consideration and under-negotiation timeline
  • Listing volume & timeline for each province
  • Market access timeline forecasting (from HTA submission to first listing)

It also includes biosimilar metrics related:

  • Oncology & non-oncology
  • Volume of funded biosimilars for each province
  • Average time to list for biosimilars for each province
  • Average time under negotiation for oncology & non-oncology biosimilars

For further information on the content and pricing of CRaFT and the Oncology and Biosimilar Sub-report, please complete your contact information on our main CRaFT Report page.

← Back to Main CRaFT Report
Canadian Reimbursement and Forecasting Timelines (CRaFT) - Oncology and Biosimilar Sub-Report, June 2021 Update